Results 171 to 180 of about 2,059,704 (313)

The acceptability of minimally invasive tissue sampling for cause of death determination in rural South Africa: A qualitative analysis. [PDF]

PLoS One
Brandt LL, Mathebula G, Mondlane ZL, Jewett S, Kahn K, Wagner RG, Price J.   +6 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Provisional estimates of selected comparability ratios based on dual coding of 1966 death certificates by the seventh and eight revisions of the International Classification of Diseases

The International Lists of Causes of Death have been revised approximately every 10 years since 1900. Each decennial revision has produced some break in the comparability of cause-of-death statistics. As described below the Eighth Revision contains major

core   +1 more source

Trends in cancer and heart disease death rates among adults aged 45\u201364: United States, 1999\u20132017

Objectives\u2014This report presents death rates for cancer and heart disease among adults aged 45\u201364 in the United States for 1999\u20132017. Rates for 1999\u20132017 are presented by sex and race and ethnicity (non-Hispanic white, non-Hispanic ...

core  

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Studying asphyxiation in the lab: the role of experimental evidence in cause-of-death inquiry. [PDF]

Hist Philos Life Sci
Fischer E, Jukola S.
europepmc   +1 more source

Uncounted causes of death [PDF]

The Lancet, 2016
openaire   +2 more sources

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Stroke's Resurgence as a Leading Cause of Death in the United States. [PDF]

Stroke
de Havenon A, Sheth KN.
europepmc   +1 more source

2020 documentation initial release : mortality multiple cause-of-death public use record [PDF]

The file layout is separate for US and territories data but both are included in this package.Publication date from document properties.Multiple-Cause-Record-Layout-2020 ...

core